Nature Communications (Jul 2018)
A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model
- Naomi Tsuburaya,
- Kengo Homma,
- Tsunehiko Higuchi,
- Andrii Balia,
- Hiroyuki Yamakoshi,
- Norio Shibata,
- Seiichi Nakamura,
- Hidehiko Nakagawa,
- Shin-ichi Ikeda,
- Naoki Umezawa,
- Nobuki Kato,
- Satoshi Yokoshima,
- Masatoshi Shibuya,
- Manabu Shimonishi,
- Hirotatsu Kojima,
- Takayoshi Okabe,
- Tetsuo Nagano,
- Isao Naguro,
- Keiko Imamura,
- Haruhisa Inoue,
- Takao Fujisawa,
- Hidenori Ichijo
Affiliations
- Naomi Tsuburaya
- Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo
- Kengo Homma
- Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo
- Tsunehiko Higuchi
- Graduate School of Pharmaceutical Sciences, Nagoya City University
- Andrii Balia
- Department of Life Science and Applied Chemistry, Nagoya Institute of Technology
- Hiroyuki Yamakoshi
- Graduate School of Pharmaceutical Sciences, Nagoya City University
- Norio Shibata
- Department of Life Science and Applied Chemistry, Nagoya Institute of Technology
- Seiichi Nakamura
- Graduate School of Pharmaceutical Sciences, Nagoya City University
- Hidehiko Nakagawa
- Graduate School of Pharmaceutical Sciences, Nagoya City University
- Shin-ichi Ikeda
- Graduate School of Pharmaceutical Sciences, Nagoya City University
- Naoki Umezawa
- Graduate School of Pharmaceutical Sciences, Nagoya City University
- Nobuki Kato
- Graduate School of Pharmaceutical Sciences, Nagoya City University
- Satoshi Yokoshima
- Graduate School of Pharmaceutical Sciences, Nagoya University
- Masatoshi Shibuya
- Graduate School of Pharmaceutical Sciences, Nagoya University
- Manabu Shimonishi
- GCOE Program, The University of Tokyo
- Hirotatsu Kojima
- Drug Discovery Initiative (DDI), The University of Tokyo
- Takayoshi Okabe
- Drug Discovery Initiative (DDI), The University of Tokyo
- Tetsuo Nagano
- Drug Discovery Initiative (DDI), The University of Tokyo
- Isao Naguro
- Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo
- Keiko Imamura
- Center for iPS Cell Research and Application (CiRA), Kyoto University
- Haruhisa Inoue
- Center for iPS Cell Research and Application (CiRA), Kyoto University
- Takao Fujisawa
- Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo
- Hidenori Ichijo
- Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, The University of Tokyo
- DOI
- https://doi.org/10.1038/s41467-018-05127-2
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 12
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurological disease that leads to loss of voluntary muscle movement. Here, the authors screen for molecules that disrupt interaction between SOD1, a protein linked to ALS, and Derlin-1, and find an inhibitor that reduces pathology in an ALS mouse model.
